Trial Profile
Clinical study protocol no. VIA-2291-01, a phase 2 randomized, double-blind, parallel-group, placebo-controlled, dose-ranging study of the effect of VIA-2291 on vascular inflammation in patients after an acute coronary syndrome event
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Atreleuton (Primary)
- Indications Acute coronary syndromes
- Focus Biomarker; Pharmacodynamics
- Acronyms ACS
- Sponsors Tallikut Pharmaceuticals
- 12 Mar 2018 Results assessing the change in epicardial fat volume after treatment with atreleuton presented at the 67th Annual Scientific Session of the American College of Cardiology
- 24 Nov 2016 Results (n=54) assessing the effect of atreleuton on coronary plague progression (serial CT angiography study) published in the Clinical Cardiology
- 20 May 2010 Results have been published in in volume 3, issue 3 of the American Heart Association journal Circulation: Cardiovascular Imaging, published May 19, 2010, according to a VIA Pharmaceuticals media release.